Bayer submits EMA application for aflibercept 8 mg third indication, retinal vein occlusion

News
Article

In the European Union and the United Kingdom, aflibercept 8 mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular oedema

A syringe and containers of liquid in front of the European Medicines Agency logo. Concept image for aflibercept Eylea EMA approval. Image credit: ©SoniaBonet – stock.adobe.com

The QUASAR trial compared aflibercept 2mg to aflibercept 8mg in patients with retinal vein occlusion. Image credit: ©SoniaBonet – stock.adobe.com

Bayer announced the submission of an application to the European Medicines Agency (EMA) seeking to expand the indication for aflibercept 8 mg. This dosage of aflibercept (Eylea) will be assessed for treatment of macular oedema following retinal vein occlusion (RVO). Central, branch and hemiretinal RVO are included in this application, Bayer said in a press release. Aflibercept 8 mg is currently approved for the treatment of patients with neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO).1

The submission is based on positive results from the phase 3 QUASAR study. In December 2024, Regeneron Pharmaceuticals announced that the trial met its primary endpoint.2 Aflibercept is being jointly developed by Bayer and Regeneron.

The QUASAR trial compared aflibercept 2 mg with aflibercept 8 mg in patients with RVO, and the primary endpoint was mean change in best corrected visual acuity (BCVA) through week 36. Patients receiving aflibercept 8mg were treated with an 8-week dosing regimen, following three or five initial monthly doses; patients receiving aflibercept 2 mg were treated every 4 weeks.2

Previous reporting from the QUASAR trial3 indicated aflibercept 8 mg results were consistent across patients with branch retinal vein occlusions, and those patients with central retinal or hemiretinal vein occlusions. Of the patients treated with aflibercept 8 mg through 36 weeks, 88% of patients were able to sustain an 8-week dosing regimen following 3 initial monthly doses, and 93% of patients maintained an 8-week dosing regimen after completing 5 initial monthly doses.

Additionally, according to the press release from Bayer1 nearly 70% of those patients had a last assigned dosing interval of 12 weeks. Fluid reduction was similar between the patient groups who received aflibercept 8 mg and aflibercept 2 mg. Finally, Bayer reported, aflibercept 8 mg was well tolerated and its safety profile was consistent with previous trials.

Christine Roth, executive vice president of global product strategy and commercialisation and member of the pharmaceuticals leadership team at Bayer, commented on the submission.1 “Today’s submission is an important step towards improving patient care in retinal vein occlusion,” she said. “Once approved, aflibercept 8 mg expands durable treatment options alleviating the burden of frequent injections and clinic visits for patients living with retinal vein occlusion.”

In the United States, Regeneron maintains exclusive rights to aflibercept 2 mg (Eylea 2 mg) and aflibercept 8 mg (Eylea HD); outside the US, Bayer has licensed exclusive marketing rights. According to prior statements2 by Regeneron, the companies are also seeking approval from the US Food and Drug Administration for the third indication of aflibercept 8 mg.

References

  1. Bayer files for approval of aflibercept 8 mg for treatment of retinal vein occlusion in EU. Press release. Bayer. Published April 8, 2025. Accessed April 9, 2025. https://firstwordpharma.com/story/5948151
  2. Harp M D. Regeneron announces aflibercept 8mg injection meets primary endpoint in phase 3 QUASAR trial in patients with retinal vein occlusion. Ophthalmology Times. Published December 17, 2024. Accessed April 9, 2025. https://www.ophthalmologytimes.com/view/regeneron-announces-aflibercept-8mg-injection-meets-primary-endpoint-in-phase-3-quasar-trial-in-patients-with-retinal-vein-occlusion
  3. Harp M D. Regeneron reveals positive results from multiple trials evaluating Eylea HD (aflibercept) injection 8 mg. Ophthalmology Times. Published February 10, 2025. Accessed April 9, 2025.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.